NasdaqGS:VRTXBiotechs
How Vertex’s Kidney Drug Breakthrough and FDA Recognition Will Impact VRTX Investors
Vertex Pharmaceuticals recently reported positive interim data from the RUBY-3 trial at ASN Kidney Week 2025, showing that its investigational kidney disease therapy povetacicept led to substantial reductions in proteinuria and favorable safety results in adults with IgA nephropathy and primary membranous nephropathy.
Alongside these clinical findings, Vertex received Breakthrough Therapy Designation from the FDA for povetacicept in IgA nephropathy, completed late-stage trial enrollment, and...